


REMARKS/ARGUMENTS

Claim 3 has been amended. Support for the amendment may be found at page 6, fifth paragraph of the specification. No new matter has been introduced by the instant claims. Claim 11 has been cancelled. Applicants reserve the right to pursue the subject matter of claim 11 in this or a subsequent application.

Applicants elect group I, compounds and compositions of claims 1-7. Applicants further elect the compound of Example 68, e.g., 4-Bromo-2-(4-isopropyl-phenyl)-7-methoxy-1-(2-methoxy-ethyl)-5-(3-methoxy-phenyl)-1H-benzimidazole in response to the species election. Claims 1-7 read on the elected species. Applicants request rejoinder of the subject matter of Groups II, III and IV, upon allowance of claims directed to group I. These elections are made without traverse.

Should the Examiner have any questions, please contact the undersigned attorney.

Respectfully submitted,



John Alexander
Attorney for Applicants
Reg. No. 48,399

Novartis Institutes for BioMedical Research
220 Massachusetts Avenue
Cambridge, MA 02139
(617) 871-3105

Date: October 29, 2009